Oxford Biomedica has appointed Lucinda Crabtree as its new chief financial officer (CFO), as Stuart Paynter steps down from the role after almost seven years in the position.

Crabtree joins from MorphoSys AG., where she also served as CFO. In her time at the firm, she led a finance team across the US and Germany until the closing of the company’s acquisition by Novartis.

Prior to this, she served as CFO as Autolus Therapeutics, after spending several years as an investment professional at institutions including Woodford Investment Management, Panmure Gordon, Goldman Sachs, J.P. Morgan and Jefferies.

Crabtree also has prior experience as a board observer at several private healthcare companies and holds a Ph.D. on pharmacology from University College London.

She will start in her role from 2 September, at which point, Paynter will begin his transition away from Oxford Biomedica following a suitable handover.

Chief executive officer at Oxford Biomedica, Dr Frank Mathias, said: "On behalf of the corporate executive team, I am delighted to welcome Crabtree to Oxford Biomedica. Her unique skillset will be immensely valuable to us as we enter the next phase of our growth as a pure-play CDMO.

"I would also like to warmly thank Paynter for his dedicated service to OXB. Since joining the company nearly seven years ago, Paynter has been instrumental in its success right the way through to the recent transformation of our business model. We wish him all the best for his future endeavours."

---